Virtual Library

Start Your Search

Taishi Harada

Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-102 - Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort (ID 12068)

      16:45 - 18:00  |  Author(s): Taishi Harada

      • Abstract


      EGFR-TKIs led to initial clinical response in most patients with EGFR mutated non-small cell lung cancer (NSCLC). In contrast, little is known the subpopulation of NSCLC patients with EGFR mutations who had clinical outcomes to treat for immune checkpoint inhibitors (ICIs). Therefore, to seek for the eligible cases to treat with ICIs, we retrospectively analyzed the correlations between clinical feature and the efficacy of ICIs in patients with EGFR mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We analyzed a retrospective study of patients with advanced NSCLC harboring with EGFR mutations who were treated with ICIs after the resistance to EGFR-TKIs between February 2016 and April 2018 at five institutions in Japan. The association between clinical outcome and the efficacy or ICIs was investigated.

      4c3880bb027f159e801041b1021e88e8 Result

      We enrolled 27 patients who had EGFR activating mutation. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (57.1% versus 6.3% and 71.4% versus 31.3%, p= 0.003 and p = 0.06, respectively). Patients with uncommon EGFR mutations were associated with a significantly longer median progression-free survival than those with common EGFR mutations (7.0 months versus 1.9 months, p = 0.009).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Uncommon EGFR mutations are associated with better outcomes for the treatment with immunotherapy among EGFR mutated NSCLC in the retrospective analysis. Further research is needed to validate for the clinical biomarkers involved in ICI responders.